|
Website:
http://www.genesis.co.nz
Phone: +64 9 373 5600 |
Address:
One Fox Street
Parnell, Auckland |
Company Description
Genesis Research and Development Corporation Limited. The Group's principal activities are the research, discovery and development of novel drugs as diverse as therapeutic vaccines for immune disorders such as psoriasis, asthma and eczema; vaccines for recalcitrant diseases such as tuberculosis; novel bio actives that diversify pharmaceutical and nutraceutical products; and gene products for use in trees and other plants to enhance the traits as the quality of wood fibre, disease-resistance, drought-resistance and salt tolerance. The core business is genomics integration of molecular and computer technologies to build and interpret libraries of DNA sequences. The Group's trademark are the AVAC, MED-1 and PVAC.
Key People
| Chief Executive | Dr. James Douglas Watson |
| Non Executive Director | Jim McLean |
| Secretary | Stephen Hall |
Breaking News
Forbes.com - August 13, 2008 7:17 PM
Cell Genesys, Inc. (Nasdaq:CEGE) today reported financial results for the second quarter ended June 30, 2008. The net loss for the quarter ended June 30, 2008, was $2.8 million ($0.03 per fully diluted share), compared to a net loss of $1.9 million ...
Christian Science Monitor - August 08, 2008 11:10 PM
Faith leaders' quest for understanding, commonality begins Tuesday at Yale. Top-tier religious leaders in the Muslim world are emerging as major proponents of dialogue with Christians and other world faiths. With two distinct initiatives this month, they ...
